Alternative Treatment Options to Levodopa and Carbidopa for Parkinson’s Disease Patients
DOI:
https://doi.org/10.47611/jsrhs.v11i3.2968Keywords:
Dopaminergic neurons, cell death, Parkinson's Disease, neuroprotection, levodopa, parkinsonismAbstract
The most commonly used treatment for Parkinson’s Disease (PD) is levodopa used in conjunction with carbidopa. Despite being able to alleviate the motor symptoms of PD, it is unable to slow down the progression of the disease or give neuroprotective effects. There is no effective cure for PD or any treatment that is able to prevent the advancement of Parkinson’s pathology. The purpose of this research was to examine different combinations of treatments and medications that provide best results for patients and investigate novel research that is conducted in order to target the causes of PD, rather than its effects and symptoms. Interviews of doctors were conducted in order to determine the most commonly used treatments and what they have had success with when treating patients. The results revealed that levodopa still remains the most effective treatment, but its effects can be improved by adjunctive medications or therapies. Recent research also suggests that drugs that target other factors of PD pathology separate from dopaminergic neurons provide more neuroprotective effects and may be able to prevent the progression of the disease.
Downloads
References or Bibliography
Amantadine: MedlinePlus Drug Information. (n.d.). Retrieved January 12, 2022, from https://medlineplus.gov/druginfo/meds/a682064.html
Approved Medications | American Parkinson Disease Assoc. (n.d.). APDA. Retrieved January 20, 2022, from https://www.apdaparkinson.org/what-is-parkinsons/treatment-medication/medication/
Brooks, D. J. (2008). Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective. Neuropsychiatric Disease and Treatment, 4(1), 39–47. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515910/
Seo, B. (2021, December 21). [Personal communication].
Calabresi, P., Filippo, M. D., Ghiglieri, V., Tambasco, N., & Picconi, B. (2010). Levodopa-induced dyskinesias in patients with Parkinson’s disease: filling the bench-to-bedside gap. The Lancet Neurology, 9(11), 1106–1117. https://doi.org/10.1016/S1474-4422(10)70218-0
Cerri, S., & Blandini, F. (2020). An update on the use of non-ergot dopamine agonists for the treatment of Parkinson’s disease. Expert Opinion on Pharmacotherapy, 21(18), 2279–2291. https://doi.org/10.1080/14656566.2020.1805432
Dawson, T., & Johns Hopkins Medicine. (2019, October 21). Pathophysiology of Parkinson's Disease | 2019 Udall Center research symposium [Video]. Youtube. https://www.youtube.com/watch?v=tr5qOe0XGJk
History of PD. (n.d.). Stanford Parkinson’s Community Outreach. Retrieved January 20, 2022, from https://med.stanford.edu/parkinsons/introduction-PD/history.html
Joshi, A. U., Minhas, P. S., Liddelow, S. A., Haileselassie, B., Andreasson, K. I., Dorn, G. W., & Mochly-Rosen, D. (2019). Fragmented mitochondria released from microglia trigger A1 astrocytic response and propagate inflammatory neurodegeneration. Nature Neuroscience, 22(10), 1635–1648. https://doi.org/10.1038/s41593-019-0486-0
Kim, S., Kwon, S.-H., Kam, T.-I., Panicker, N., Karuppagounder, S. S., Lee, S., Lee, J. H., Kim, W. R., Kook, M., Foss, C. A., Shen, C., Lee, H., Kulkarni, S., Pasricha, P. J., Lee, G., Pomper, M. G., Dawson, V. L., Dawson, T. M., & Ko, H. S. (2019). Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson’s Disease. Neuron, 103(4), 627-641.e7. https://doi.org/10.1016/j.neuron.2019.05.035
Levodopa and Carbidopa: MedlinePlus Drug Information. (2022, January 15). https://medlineplus.gov/druginfo/meds/a601068.html
Mak, M. K., Wong-Yu, I. S., Shen, X., & Chung, C. L. (2017). Long-term effects of exercise and physical therapy in people with Parkinson disease. Nature Reviews. Neurology, 13(11), 689–703. https://doi.org/10.1038/nrneurol.2017.128
Olanow, C. W., Kieburtz, K., Leinonen, M., Elmer, L., Giladi, N., Hauser, R. A., Klepiskaya, O. S., Kreitzman, D. L., Lew, M. F., Russell, D. S., Kadosh, S., Litman, P., Friedman, H., Linvah, N., & The P B Study Group, F. (2017). A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson’s disease. Movement Disorders: Official Journal of the Movement Disorder Society, 32(5), 783–789. https://doi.org/10.1002/mds.26941
Pandey, S., & Srivanitchapoom, P. (2017). Levodopa-induced Dyskinesia: Clinical Features, Pathophysiology, and Medical Management. Annals of Indian Academy of Neurology, 20(3), 190–198. https://doi.org/10.4103/aian.AIAN_239_17
Panicker, N., Ge, P., Dawson, V. L., & Dawson, T. M. (2021). The cell biology of Parkinson’s disease. The Journal of Cell Biology, 220(4), e202012095. https://doi.org/10.1083/jcb.202012095
Parker, J. G., Marshall, J. D., Ahanonu, B., Wu, Y.-W., Kim, T. H., Grewe, B. F., Zhang, Y., Li, J. Z., Ding, J. B., Ehlers, M. D., & Schnitzer, M. J. (2018). Diametric neural ensemble dynamics in parkinsonian and dyskinetic states. Nature, 557(7704), 177–182. https://doi.org/10.1038/s41586-018-0090-6
Side Effects of Sinemet (Carbidopa-Levodopa), Warnings, Uses. (n.d.). RxList. Retrieved January 28, 2022, from https://www.rxlist.com/sinemet-side-effects-drug-center.htm
Stages of Parkinson’s | Parkinson’s Foundation. (n.d.). Retrieved January 20, 2022, from https://www.parkinson.org/Understanding-Parkinsons/What-is-Parkinsons/Stages-of-Parkinsons
Statistics | Parkinson’s Foundation. (n.d.). Retrieved November 5, 2021, from https://www.parkinson.org/Understanding-Parkinsons/Statistics
Valera, E., Monzio Compagnoni, G., & Masliah, E. (2016). Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy. Neuropathology and applied neurobiology, 42(1), 95–106. https://doi.org/10.1111/nan.12312
Vijayakumar, D., & Jankovic, J. (2016). Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia. Drugs, 76(7), 759–777. https://doi.org/10.1007/s40265-016-0566-3
Von Coelln, F. R. (2021, December 6). [Personal communication].
Von Coelln, F. R. (2022, March 26). [Personal communication].
Yun, S. P., Kam, T.-I., Panicker, N., Kim, S., Oh, Y., Park, J.-S., Kwon, S.-H., Park, Y. J., Karuppagounder, S. S., Park, H., Kim, S., Oh, N., Kim, N. A., Lee, S., Brahmachari, S., Mao, X., Lee, J. H., Kumar, M., An, D., … Ko, H. S. (2018). Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease. Nature Medicine, 24(7), 931–938. https://doi.org/10.1038/s41591-018-0051-5
Zaaroor, M., Sinai, A., Goldsher, D., Eran, A., Nassar, M., & Schlesinger, I. (2018). Magnetic resonance-guided focused ultrasound thalamotomy for tremor: a report of 30 Parkinson’s disease and essential tremor cases. Journal of Neurosurgery, 128(1), 202–210. https://doi.org/10.3171/2016.10.JNS16758
Published
How to Cite
Issue
Section
Copyright (c) 2022 Destany Kwon; Jing Wang, Janine Sharbaugh
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
